Had dinner with a friend tonight, she knows I dabble in stocks and asked if "anything interesting" was happening. So I talked a little about Trius and how it's an antibiotic yadda yadda and I mentioned it was for MRSA. She then tells me that she was recently given an IV antibiotic due to a skin infection (very minor and one dose of what she couldn't remember). Anyway, she goes on to tell me her and her friend (whom she tired to set me up with a few years ago) recently went on a day trip and all her friend talked about was being worried about her job as the company is freaking out about one of the drugs going generic.
She is a REP for Pfizer (I knew that) and her main drug is Zyvox (I didn't know that until tonight).
I'm not saying Pfizer is looking at Trius or anything because I don't know. This was just a very odd coincidence that happened to me tonight that I wanted to share. I think things might get very interesting for Truis given the conversation I had this evening.
Here is a little info I found on Jeffrey Stein, the CEO of Trius on the Trius web site.
From 1999 to 2005, Dr. Stein served as executive vice president, chief scientific officer and a member of the board of directors of Quorex Pharmaceuticals, an anti-infectives company he founded in 1999, which was acquired by Pfizer in 2005.